Biopharma Capital Is Returning. Getting to the Clinic Is Still the Challenge. Ivan Lim, Doug Brown - 12 Nov 2026 Biopharma M&A Is Back. Leadership Will Decide Which Deals Pay Off. Ivan Lim, Doug Brown - 21 Oct 2026